Otsuka Korea begins SWAT study

Published: 2004-11-10 06:56:00

Updated: 2004-11-10 06:56:00

Otsuka Korea said that since the end of October, it has began conducting its local SWAT (SWitching of Abilify Trial) study to evaluate the safety and efficacy of Abilify, including its tolerability, which was launched earlier this year, after physicians prescribed Abilify to patients with schizop...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK